Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2',3'-Dideoxycytidine‐5'‐monophosphate (ddCMP)** is a synthetic nucleoside analog belonging to the class of pyrimidones. Structurally derived from cytidine by removal of the hydroxyl groups at the 2' and 3' positions and phosphorylation at the 5' position, ddCMP acts as an antiviral agent primarily studied for its activity against retroviruses such as HIV. Its mechanism involves incorporation into viral DNA or RNA by viral polymerases; once incorporated, it functions as a chain terminator due to its lack of a necessary hydroxyl group for further elongation. This halts viral genome synthesis and inhibits replication[1][2][3]. It is considered experimental and not approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2',3'-dideoxycytidine-5'-monophosphate.